MY104530A - Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. - Google Patents
Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.Info
- Publication number
- MY104530A MY104530A MYPI90002043A MYPI19902043A MY104530A MY 104530 A MY104530 A MY 104530A MY PI90002043 A MYPI90002043 A MY PI90002043A MY PI19902043 A MYPI19902043 A MY PI19902043A MY 104530 A MY104530 A MY 104530A
- Authority
- MY
- Malaysia
- Prior art keywords
- hiv
- recombinant
- particles
- nonreplicating
- immunogens
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 230000001177 retroviral effect Effects 0.000 title abstract 4
- 239000003443 antiviral agent Substances 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 241001430294 unidentified retrovirus Species 0.000 title 1
- 241000700618 Vaccinia virus Species 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 230000000877 morphologic effect Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 230000034303 cell budding Effects 0.000 abstract 1
- 108700004025 env Genes Proteins 0.000 abstract 1
- 101150030339 env gene Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
NONREPLICATING RECOMBINANT- MADE RETROVIRAL PARTICLES HAVING STRUCTURAL, MORPHOLOGICAL AND IMMUNOLOGICAL CHARACTERICTICS VERY SIMILAR TO THOSE OF NATIVE HUMAN RETROVIRUSES ARE DESCRIBED. THE METHOD OF THE INVENTION INVOLVES COEXPRESSION OF MATURE RETROVIRAL CORE AND ENVOLOPE STRUCTURAL PROTEINS IN MAMMALIAN HOST CELLS SUCH THAT THE EXPRESSED RETROOVIRAL PROTEINS ASSOCIATE INTO ASSEMBLED BUDDING RETROVIRAL PARTICLES. IN A PARTICULAR EMBODIMENT OF THE INVENTION NONREPLICATING RECOMBINANT- MADE HIV- 1 PARTICLES ARE PRODUCED BY COINFACTING MAMMALIAN HOST CELLS WITH A RECOMBINANT VACCINIA VIRUS CARRYING THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV- 1) GAG AND PROTEASE GENES AND A RECOMBINANT VACCINIA VIRUS CARRYING THE HIV- 1 ENV GENE. THESE NONREPLICATING RECOMBINANT- MADE HIV- 1PARTICLES HAVE IMMUNOLOGICAL AND MORPHOLOGICAL CHARACTERISTICS CLOSELY RESEMBLING THOSE OF NATIVE HIV- 1, ARE ABLE TO BLOCK THE INFECTIVITY OF LIVE HIV IN VITRO, AND ARE HIGHLY IMMUNOGENIC IN VIVO. THE RECOMBINANT- MADE HIV- 1 PARTICLES OF THE INVENTION MAY BE USED AS ANTI- VIRAL AGENTS AND AS IMMUNOGENS IN VACCINE FORMULATIONS EFFECTIVE AT INHIBITING OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43920589A | 1989-11-20 | 1989-11-20 | |
| US61575690A | 1990-11-19 | 1990-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY104530A true MY104530A (en) | 1994-04-30 |
Family
ID=27031958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI90002043A MY104530A (en) | 1989-11-20 | 1990-11-20 | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN1054613A (en) |
| IE (1) | IE904161A1 (en) |
| IL (1) | IL96404A0 (en) |
| MY (1) | MY104530A (en) |
| PT (1) | PT95939A (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
| US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
| US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| ATE369427T1 (en) | 2001-03-22 | 2007-08-15 | Us Health | GLYCOSYLATION-RESISTANT CYANOVIRINS AND ASSOCIATED CONJUGATES, COMPOSITIONS, NUCLEIC ACIDS, VECTORS, HOST CELLS, PRODUCTION METHODS AND METHODS FOR USING NON-GLYCOSYLATED CYANOVIRINS |
| CN104450631A (en) * | 2014-11-11 | 2015-03-25 | 中国人民解放军第四军医大学 | Enterovirus EV71 type VP1 gene virus-like particle as well as preparation method and application thereof |
-
1990
- 1990-11-19 IL IL9096404A patent/IL96404A0/en unknown
- 1990-11-19 IE IE416190A patent/IE904161A1/en unknown
- 1990-11-20 PT PT9593990A patent/PT95939A/en not_active Application Discontinuation
- 1990-11-20 CN CN 90110329 patent/CN1054613A/en active Pending
- 1990-11-20 MY MYPI90002043A patent/MY104530A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE904161A1 (en) | 1991-05-22 |
| PT95939A (en) | 1991-09-13 |
| IL96404A0 (en) | 1991-08-16 |
| CN1054613A (en) | 1991-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO921969L (en) | NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | |
| Karacostas et al. | Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. | |
| Binley et al. | Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins | |
| Hahn et al. | Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. | |
| DK33190A (en) | HIV-3 RETROVIRUS AND ITS USE | |
| Göttlinger et al. | Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. | |
| Morikawa et al. | Identification and analysis of the gag-pol ribosomal frameshift site of feline immunodeficiency virus | |
| DK0495811T3 (en) | Production of genetically engineered vaccines against AIDS and other retroviral diseases | |
| CA2243570A1 (en) | Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv | |
| WO1990015066A3 (en) | Nucleotidic sequences resulting from the retrovirus gemone of the hiv-1, hiv-2, and siv type, and their applications, in particular for the amplification of the genomes of said retroviruses and for the in vitro diagnosis of infections caused by these viruses | |
| IL89701A0 (en) | Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same | |
| WO1991002805A3 (en) | Recombinant retroviruses delivering vector constructs to target cells | |
| FR2606029B2 (en) | VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED | |
| JP2004509601A5 (en) | ||
| Yourno et al. | Nucleotide sequence analysis of the env gene of a new Zairian isolate of HIV-1 | |
| Matthews et al. | Prospects for development of a vaccine against HTLV-III-related disorders | |
| Sharova et al. | p17 and p17-containing gag precursors of input human immunodeficiency virus are transported into the nuclei of infected cells | |
| RU2006123079A (en) | VIRUS PARTICLES CONTAINING A VECTOR ORIGINING FROM ALPHAVIRUS AND METHOD FOR PRODUCING THE SPECIFIED VIRUS PARTICLE | |
| FR2600079B1 (en) | VIRAL VECTOR AND RECOMBINANT DNA ENCODING PROTEIN F OF THE VIRUS CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING THE PROTEIN, OBTAINED PROTEIN, VACCINE AND ANTIBODIES OBTAINED | |
| WO2022035860A3 (en) | Replication-competent adenovirus type 4-hiv env vaccines and their use | |
| CA2330618A1 (en) | Viral chimeras comprised of caev and hiv-1 genetic elements | |
| Galabru et al. | Nucleotide sequence of the HIV-2 EHO genome, a divergent HIV-2 isolate | |
| CA2339850A1 (en) | A non-cytolytic recombinant hiv-1 vaccine | |
| Ranjbar et al. | Molecular characterization of an HIV type 1 isolate from Burundi | |
| Ferdinand et al. | Perspectives of HIV vaccine developments |